Skip to main content
Journal of Neuroinflammation logoLink to Journal of Neuroinflammation
. 2011 Aug 11;8:97. doi: 10.1186/1742-2094-8-97

Vascular endothelial growth factor-A (VEGF-A) and chemokine ligand-2 (CCL2) in amyotrophic lateral sclerosis (ALS) patients

Pawan K Gupta 1,#, Sudesh Prabhakar 1,#, Suresh Sharma 2, Akshay Anand 1,
PMCID: PMC3199788

Abstract

Correction to Gupta P K, Prabhakar S, Sharma S, Anand A. Vascular endothelial growth factor-A (VEGF-A) and chemokine ligand-2 (CCL2) in amyotrophic lateral sclerosis (ALS) patients. Journal of Neuroinflammation 8:47.

Correction

The authors observe that, in Table two of our study [1], crude ORs and adjusted ORs for serum VEGFA were also repeated for CSF VEGFA, however, these values for CSF VEGFA are different from serum VEGFA. Correct OR values of CSF VEGFA are given below.

Smoking: [crude OR(95% CI) = 1.7 (0.3-9.1), p = 0.4; adj OR (95% CI) = 0.6 (0.08-4.4), p = 0.6].

Alcohol consumption: [crude OR(95% CI) = 0.6 (0.1-2.2), p = 0.4; adj OR (95% CI) = 0.8 (0.1-4.4), p = 0.8].

Meat consumption: [crude OR(95% CI) = 2.2 (0.6-7.7), p = 0.2; adj OR (95% CI) = 2.1 (0.5-7.7), p = 0.2].

Contributor Information

Pawan K Gupta, Email: ace_pawan@yahoo.co.in.

Sudesh Prabhakar, Email: drsprabhakar@gmail.com.

Suresh Sharma, Email: ssharma643@yahoo.co.in.

Akshay Anand, Email: akshay1anand@rediffmail.com.

References

  1. Gupta PK, Prabhakar S, Sharma S, Anand A. Vascular endothelial growth factor-A (VEGF-A) and chemokine ligand-2 (CCL2) in amyotrophic lateral sclerosis (ALS) patients. J Neuroinflammation. p. 47. [DOI] [PMC free article] [PubMed]

Articles from Journal of Neuroinflammation are provided here courtesy of BMC

RESOURCES